Cyclerion Therapeutics, Inc. (CYCN)

USD 2.85

(-13.26%)

Market Cap (In USD)

7.71 Million

Revenue (In USD)

-

Net Income (In USD)

-21.01 Million

Avg. Volume

5307.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.27-9.47
PE
-
EPS
-
Beta Value
1.924
ISIN
US23255M2044
CUSIP
23255M105
CIK
1755237
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Regina Graul Ph.D.
Employee Count
-
Website
https://www.cyclerion.com
Ipo Date
2019-03-18
Details
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.